NCT00000812View on ClinicalTrials.gov

A Phase I, Placebo-Controlled, Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Thalidomide in Subjects With HIV-1 Infection

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

Not specified

Study Completion Date

July 31, 2000

Conditions
HIV Infections
Interventions
DRUG

Thalidomide

Trial Locations (6)

10021

Memorial Sloan-Kettering Cancer Ctr., New York

19104

Hosp. of the Univ. of Pennsylvania CRS, Philadelphia

44106

Case CRS, Cleveland

55455

University of Minnesota, ACTU, Minneapolis

80262

University of Colorado Hospital CRS, Aurora

275997215

Unc Aids Crs, Chapel Hill

Sponsors

Collaborators (1)

Celgene Corporation
All Listed Sponsors
collaborator

Celgene Corporation

INDUSTRY

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00000812 - A Phase I, Placebo-Controlled, Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Thalidomide in Subjects With HIV-1 Infection | Biotech Hunter | Biotech Hunter